Currently, there are 54.58M common shares owned by the public and among those 50.81M shares have been available to trade.
The company’s stock has a 5-day price change of -84.15% and -86.73% over the past three months. MRNS shares are trading -88.04% year to date (YTD), with the 12-month market performance down to -82.13% lower. It has a 12-month low price of $5.57 and touched a high of $11.26 over the same period. MRNS has an average intraday trading volume of 443.91K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -85.00%, -85.96%, and -84.75% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shares accounts for 94.03% of the company’s 54.58M shares outstanding.
It has a market capitalization of $71.03M and a beta (3y monthly) value of 0.92. The earnings-per-share (ttm) stands at -$2.63. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.74% over the week and 8.96% over the month.
Analysts forecast that Marinus Pharmaceuticals Inc (MRNS) will achieve an EPS of $Marinus Pharmaceuticals, Inc. for the current quarter, $1.30 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Varonis Systems, Inc. while analysts give the company a high EPS estimate of $Tidal Trust II. Comparatively, EPS for the current quarter was $Mersana Therapeutics, Inc. a year ago. Earnings per share for the fiscal year are expected to increase by 14.88%, and 30.85% over the next financial year. EPS should grow at an annualized rate of 20.00% over the next five years, compared to 6.04% over the past 5-year period.
Looking at the support for the MRNS, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Sector Perform rating for the stock in a research note on Apr-16-24, with the firm’s price target at $24-$3. Oppenheimer coverage for the Marinus Pharmaceuticals Inc (MRNS) stock in a research note released on August 11, 2023 offered a Perform rating with a price target of $9. RBC Capital Mkts was of a view on January 20, 2023 that the stock is Outperform, while Truist gave the stock Buy rating on September 30, 2020, issuing a price target of $35. H.C. Wainwright on their part issued Buy rating on July 01, 2020.
